A novel adenosine 2A receptor antagonist HZ-086 enhances the efficiency of immunotherapy and alleviates the acquired resistance to PD-L1 by restoration of T cell functions

DOI: 10.1016/j.ejphar.2025.177535 Publication Date: 2025-03-20T01:27:20Z